Breaking News
Get 40% Off 0
💰 Ray Dalio just increased his holdings in Google by 162.61% - See the full portfolio with InvestingPro’s free Stock Ideas tool Copy Portfolios
Close

Amneal Pharmaceuticals Inc Class A (AMRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Amneal Pharma A's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.870 +0.020    +0.29%
- Closed. Currency in USD ( Disclaimer )
After Hours
6.870
0.000
0.00%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 940,783
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 6.820 - 6.975
Amneal Pharma A 6.870 +0.020 +0.29%

Amneal Pharmaceuticals Inc Class A Company Profile

 
Get an in-depth profile of Amneal Pharmaceuticals Inc Class A, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

7600

Equity Type

ORD

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Contact Information

Address 400 Crossing Boulevard 3rd Floor
Bridgewater, 08807
United States
Phone 908 947 3120
Fax 908 947 3146

Top Executives

Name Age Since Title
Chintu Patel 49 2002 Co-Founder, Co-CEO & Director
Chirag K. Patel 54 2005 Co-Founder, Co-CEO, President & Director
Paul M. Meister 68 2019 Independent Chairman of the Board
Gautam Patel 50 2018 Director
J. Kevin Buchi 68 2018 Independent Director
Emily Peterson Alva 47 2018 Independent Director
Deborah M. Autor 55 2022 Independent Director
Ted C. Nark 65 2018 Independent Director
Shlomo Yanai 71 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AMRX Comments

Write your thoughts about Amneal Pharmaceuticals Inc Class A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nikunj Patel
Nikunj Patel Mar 31, 2023 6:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great entry point. Q3-Q4 target $2.25-2.75
Alexandru Eva
Alexandru Eva Nov 23, 2021 4:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BUY
Despoina Alterlife
Despoina Alterlife Nov 23, 2021 4:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
are you still here my Eva ?
Zoran Labus
Zoran Labus Mar 25, 2021 11:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Robert Nicholas
Robert Nicholas Mar 05, 2021 1:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think its got a shot , they make a lot of money for how cheap they are.
burnett bryant
burnett bryant Feb 04, 2021 11:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Charles Resheske
Charles Resheske Dec 03, 2020 7:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
breakout up trend buy
Ante Parcina
Ante Parcina Nov 06, 2020 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ready to fly
Sorin Costache
Sorin Costache Sep 12, 2020 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to buy!
Istvan Nagy
Istvan Nagy Aug 06, 2020 10:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why did it drop 12% after a better than expected earnings report??
Matija Ivic
Matija Ivic Aug 06, 2020 10:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I was also suprised. Anyone have any information?
Оля Раваева
Оля Раваева Aug 06, 2020 10:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Maybe there is some undisclosed information?
Jaafar Abu
Jaafar Abu Jul 16, 2020 6:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Paolo gerosa why you say see you at 13? Its possible to get 13? What is your opinion ?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email